Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose
phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy
volunteers (NHV). The safety and pharmacokinetics of 2-DG are assessed after single or
multiple intranasal administrations.